References
- Agner T. Compliance among patients with atopic eczema. Acta Derm Venereol 2005;215:s33–s35
- Thestrup-Pedersen K. Treatment strategies and compliance for the adult patient with atopic eczema. Acta Derm Venereol 2005;215:s36–s40
- Koda M, Young L, Kradjan W, et al. Applied therapeutics: the clinical usage of drugs. 8th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2004:38–39
- Marks R, Pongsehirum D, Saylan T. A method for the assay of topical corticosteroids. Br J Dermatol 1973;88:69–74
- Hanifin JM, Cooper KD, Ho VC. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology. J Am Acad Dermatol 2004;50:391–404
- Raposo SC, Simões SD, Almeida AJ, Ribeiro HM. Advanced systems for glucocorticoids dermal delivery. Expert Opin Drug Deliv 2013;10:857--877
- Fang JY, Leu YL, Wang YY, Tsai YH. In vitro topical application and in vivo pharmacodynamic evaluation of nonivamide hydrogels using Wistar rat as an animal model. Eur J Pharm Sci 2002;15:417–423
- Tavares R, Salgado S, Raposo S, et al. Emulsões não iónicas como transportadores de glucocorticoides: estudos de cedências e permeação. Revista Portuguesa de Farmácia 2011;LII:139
- Valotis A, Neukam K, Elert O, Högger P. Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate. J Pharm Sci 2004;93:1337–1350
- Teng XW, Cutler DC, Davies NM. Degradation kinetics of mometasone furoate in aqueous systems. Int J Pharmaceutics 2003;259:129–141
- European Pharmacopeia 6.0 – microbiological examination of non sterile products, 2008, 1, 2.6.12
- GUIDELINE ICH. Q2 (R1). Validation of analytical procedures, text and methodology. EU: Adopted by CPMP, November 94. Issued as CPMP/ICH/381/95, 2005:2–15
- GUIDELINE EMEA. Stability testing: of existing active substances and related finished products. Issued as CPMP/QWP/122/02, 2003:5–13
- Farmacopeia Portuguesa 8, Lisboa: INFARMED/Ministério da Saúde e Instituto Nacional da Farmácia e do Medicamento, 157–159
- Guidance document for the conduct of skin absorption studies. Paris: Organization for Economic Cooperation and Development; 2004
- Young JM, De Young LM. Cutaneous models of inflammation for the evaluation of topical and systemic pharmacological agents. In: Spector J, Back N, Liss AR, eds. Pharmacological methods in the control of inflammation. New York: Alan R. Liss, Inc.; 1989:215–231
- Ferrão E, Salgado A, Bronze MR, Ribeiro H. Desenvolvimento e avaliação sensorial de formulações para aplicação no couro cabeludo. Revista Lusófona de Ciências e Tecnologias da Saúde 2007;4:242–250
- Magnusson BM, Cross SE, Winckle G, Roberts MS. Determination of in vitro permeability and tissue reservoir characteristics in human skin layers. Skin Pharmacol Physiol 2006;19:336–342
- Patel RP, Kamani R. Formulation, optimization and evaluation of mometasone furoate gel. J Pharm Res 2009;2:1842–1847
- Hadgraft J, Lane M. Skin permeation: the years of enlightenment. Int J Pharm 2005;305:2–12
- Vickers CF. Existence of reservoir in the SC. Arch Dermatol 1963;88:20–23
- Abidi A, Ahmad F, Singh SK, Kumar A. Comparison of reservoir effect of topical corticosteroids in an experimental animal model by histamine-induced wheal suppression test. Indian J Pharmacol 2012;44:722–725